# Biotech Daily Digest — 2025-09-13

**9 items from 2 sources**

## Summary by Source

- Endpoints News: 5 items
- Fierce Biotech: 4 items


## Endpoints News

- **[Novo Nordisk’s ongoing challenges; Summit’s Western data disappoint; Eli Lilly offers free AI access to startups; and more](https://endpoints.news/novo-nordisks-ongoing-challenges-summits-western-data-disappoint-eli-lilly-offers-free-ai-access-to-startups-and-more/)**  
  _Sat, 13 Sep 2025 10:00:40 +0000_  
  Welcome back to another edition of Endpoints Weekly! It’s conference season here in New York, and our reporters have been in and around the city chatting with all sorts of folks. Thankfully, the weather has ...

- **[AstraZeneca halts another UK investment, following Merck and Lilly moves](https://endpoints.news/astrazeneca-halts-another-uk-investment-following-merck-and-lilly-moves/)**  
  _Fri, 12 Sep 2025 19:37:36 +0000_  
  AstraZeneca is halting a $271 million investment in its Cambridge research site, the third pharma company this week to reconsider its commitment to expand in the UK.

 “We constantly reassess the investment needs of our ...

- **[Top drug regulator pushes back on report that FDA wants to 'abandon' some adcomms](https://endpoints.news/top-drug-regulator-denies-report-that-fda-wants-to-abandon-some-adcomms/)**  
  _Fri, 12 Sep 2025 18:22:06 +0000_  
  The FDA's top drug regulator denied a report that said he might "abandon" certain advisory committee meetings that often review controversial drug candidates before potential approval.

 Center for Drug Evaluation and Research Director George Tidmarsh ...

- **[Lilly loses bid to overturn $183.7M judgment in Medicaid rebate fight](https://endpoints.news/lilly-loses-bid-to-overturn-183-7m-judgment-in-medicaid-rebate-fight/)**  
  _Fri, 12 Sep 2025 15:59:58 +0000_  
  Eli Lilly must pay $183.7 million in damages in a case alleging it underpaid drug rebates to Medicaid, a federal appeals court ruled.

 The US Court of Appeals for the Seventh Circuit on Thursday  ...

- **[Lilly’s UK Gateway Labs plans uncertain in new blow to region's biopharma industry](https://endpoints.news/lillys-uk-gateway-labs-plans-uncertain-in-new-blow-to-regions-biopharma-industry/)**  
  _Fri, 12 Sep 2025 15:19:34 +0000_  
  Eli Lilly said that it's “not yet in a position to finalize” plans to bring its Gateway Labs to the UK, as it is “awaiting more clarity” on the state of the country’s life sciences ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/astrazeneca-pauses-271m-expansion-uk-latest-big-pharma-buck-britain" hreflang="en">AstraZeneca pauses $271M expansion in UK—the latest Big Pharma to buck Britain</a>](https://www.fiercebiotech.com/biotech/astrazeneca-pauses-271m-expansion-uk-latest-big-pharma-buck-britain)**  
  _Sep 12, 2025 2:20pm_  
  AstraZeneca has paused a 200 million pound sterling (about $271 million) investment in its Cambridge, England, research site, the latest Big Pharma to pull back from the U.K. this week, a company spokesperson has confirmed to Fierce Biotech.

- **[<a href="https://www.fiercebiotech.com/biotech/eli-lilly-reconsiders-uk-biotech-incubator-pauses-buildout-report" hreflang="en">Eli Lilly reconsiders UK biotech incubator, pauses buildout </a>](https://www.fiercebiotech.com/biotech/eli-lilly-reconsiders-uk-biotech-incubator-pauses-buildout-report)**  
  _Sep 12, 2025 11:42am_  
  Eli Lilly is reconsidering plans for its U.K. biotech-focused Gateway Labs amid concerns about the industry’s outlook in the country and low government spend on drug development, according to reports from several outlets.

- **[<a href="https://www.fiercebiotech.com/medtech/philips-masimo-re-patient-monitoring-partnership-broader-ai-commercial-focus" hreflang="en">Philips, Masimo re-up patient monitoring partnership with broader AI, commercial focus</a>](https://www.fiercebiotech.com/medtech/philips-masimo-re-patient-monitoring-partnership-broader-ai-commercial-focus)**  
  _Sep 12, 2025 11:16am_  
  Philips and Masimo are renewing their yearslong collaboration with an expanded focus on developing next-gen vital sign readers.

- **[<a href="https://www.fiercebiotech.com/biotech/galimedix-seeks-phase-2-funding-after-oral-alzheimers-candidate-clears-safety-test" hreflang="en">Galimedix starts phase 2 fundraise after oral Alzheimer’s candidate clears safety test</a>](https://www.fiercebiotech.com/biotech/galimedix-seeks-phase-2-funding-after-oral-alzheimers-candidate-clears-safety-test)**  
  _Sep 12, 2025 11:00am_  
  Maryland-based biotech Galimedix Therapeutics is ready to take a big swing on its oral Alzheimer’s disease candidate after the small molecule caused no serious adverse events and successfully crossed the blood-brain barrier in a phase 1 trial.
